Literature DB >> 24855070

Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?

Scott Y H Kim1, Raymond De Vries2, Sonali Parnami3, Renee Wilson4, H Myra Kim5, Samuel Frank6, Robert G Holloway7, Karl Kieburtz8.   

Abstract

BACKGROUND: Desire for improvement in one's illness and having one's own doctor functioning as a researcher are thought to promote therapeutic misconception (TM), a phenomenon in which research subjects are said to conflate research with treatment.
PURPOSE: To examine whether subjects' therapeutic motivation and own doctor functioning as researcher are associated with TM.
METHODS: We interviewed 90 persons with advanced Parkinson's disease (PD) enrolled or intending to enrol in sham surgery controlled neurosurgical trials, using qualitative interviews. Subjects were compared by motivation (primarily therapeutic vs primarily altruistic or dually motivated by altruistic and therapeutic motivation), and by doctor status (own doctor as site investigator vs not) on the following: understanding of purpose of study; understanding of research procedures; perception of chance of direct benefit; and recollection and perceptions concerning the risks.
RESULTS: 60% had primarily therapeutic motivation and 44% had their own doctor as the site investigator, but neither were generally associated with increased TM responses. Overall level of understanding of purpose and procedures of research were high. Subjects responded with generally high estimates of probability of direct benefit, but their rationales were personal and complex. The therapeutic-motivation group was more sensitive to risks. Five (5.6%) subjects provided incorrect answers to the question about purpose of research, and yet, showed excellent understanding of research procedures.
CONCLUSIONS: In persons with PD involved in sham surgery clinical trials, being primarily motivated by desire for direct benefit to one's illness or having one's own doctor as the site investigator were not associated with greater TM responses. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Clinical trials; Decision-making; Gene Therapy/Transfer; Policy Guidelines/Inst. Review Boards/Review Cttes.; Research Ethics

Mesh:

Year:  2014        PMID: 24855070      PMCID: PMC4241180          DOI: 10.1136/medethics-2013-101987

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  18 in total

1.  Therapeutic misconception in clinical research: frequency and risk factors.

Authors:  Paul S Appelbaum; Charles W Lidz; Thomas Grisso
Journal:  IRB       Date:  2004 Mar-Apr

2.  Therapeutic misconception and the appreciation of risks in clinical trials.

Authors:  Charles W Lidz; Paul S Appelbaum; Thomas Grisso; Michelle Renaud
Journal:  Soc Sci Med       Date:  2004-05       Impact factor: 4.634

3.  Therapeutic misconception in early phase gene transfer trials.

Authors:  Gail E Henderson; Michele M Easter; Catherine Zimmer; Nancy M P King; Arlene M Davis; Barbra Bluestone Rothschild; Larry R Churchill; Benjamin S Wilfond; Daniel K Nelson
Journal:  Soc Sci Med       Date:  2005-07-05       Impact factor: 4.634

4.  An approach to evaluating the therapeutic misconception.

Authors:  Scott Y H Kim; Lauren Schrock; Renee M Wilson; Samuel A Frank; Robert G Holloway; Karl Kieburtz; Raymond G de Vries
Journal:  IRB       Date:  2009 Sep-Oct

5.  Research participants' "irrational" expectations: common or commonly mismeasured?

Authors:  Scott Y H Kim; Raymond de Vries; Renee Wilson; Sonali Parnami; Samuel Frank; Karl Kieburtz; Robert G Holloway
Journal:  IRB       Date:  2013 Jan-Feb

6.  False hopes and best data: consent to research and the therapeutic misconception.

Authors:  P S Appelbaum; L H Roth; C W Lidz; P Benson; W Winslade
Journal:  Hastings Cent Rep       Date:  1987-04       Impact factor: 2.683

7.  Professional integrity in clinical research.

Authors:  F G Miller; D L Rosenstein; E G DeRenzo
Journal:  JAMA       Date:  1998-10-28       Impact factor: 56.272

8.  Ethics of phase 1 oncology studies: reexamining the arguments and data.

Authors:  Manish Agrawal; Ezekiel J Emanuel
Journal:  JAMA       Date:  2003-08-27       Impact factor: 56.272

9.  Sham surgery controls in Parkinson's disease clinical trials: views of participants.

Authors:  Scott Y H Kim; Raymond De Vries; Robert G Holloway; Renee Wilson; Sonali Parnami; H Myra Kim; Samuel Frank; Karl Kieburtz
Journal:  Mov Disord       Date:  2012-08-23       Impact factor: 10.338

10.  Clinical trials and medical care: defining the therapeutic misconception.

Authors:  Gail E Henderson; Larry R Churchill; Arlene M Davis; Michele M Easter; Christine Grady; Steven Joffe; Nancy Kass; Nancy M P King; Charles W Lidz; Franklin G Miller; Daniel K Nelson; Jeffrey Peppercorn; Barbra Bluestone Rothschild; Pamela Sankar; Benjamin S Wilfond; Catherine R Zimmer
Journal:  PLoS Med       Date:  2007-11-27       Impact factor: 11.069

View more
  7 in total

Review 1.  Living laboratory: whole-genome sequencing as a learning healthcare enterprise.

Authors:  M Angrist; L Jamal
Journal:  Clin Genet       Date:  2014-09-06       Impact factor: 4.438

2.  Parental Enrollment Decision-Making for a Neonatal Clinical Trial.

Authors:  Elliott Mark Weiss; Katherine F Guttmann; Aleksandra E Olszewski; Brooke E Magnus; Sijia Li; Scott Y H Kim; Anita R Shah; Sandra E Juul; Yvonne W Wu; Kaashif A Ahmad; Ellen Bendel-Stenzel; Natalia A Isaza; Andrea L Lampland; Amit M Mathur; Rakesh Rao; David Riley; David G Russell; Zeynep N I Salih; Carrie B Torr; Joern-Hendrik Weitkamp; Uchenna E Anani; Taeun Chang; Juanita Dudley; John Flibotte; Erin M Havrilla; Alexandra C O'Kane; Krystle Perez; Brenda J Stanley; Seema K Shah; Benjamin S Wilfond
Journal:  J Pediatr       Date:  2021-08-14       Impact factor: 4.406

3.  Clinical features of Parkinson's disease patients are associated with therapeutic misconception and willingness to participate in clinical trials.

Authors:  Emmi Reijula; Anna-Maija Pietilä; Arja Halkoaho; Tuomas Selander; Kirsti Martikainen; Reetta Kälviäinen; Tapani Keränen
Journal:  Trials       Date:  2017-09-29       Impact factor: 2.279

4.  Raising Awareness of Therapeutic Misconception and Optimism Around Clinical Trials in Huntington's Disease.

Authors:  Susanne Tamara de Bot
Journal:  J Huntingtons Dis       Date:  2019

5.  Patient and Caregiver Experiences of Participating in Parkinson's Disease Clinical Trials: A Systematic Review of Qualitative Studies.

Authors:  Olivia Gorzynska; Katie McGoohan; Latha Velayudhan
Journal:  Arch Clin Neuropsychol       Date:  2022-02-22       Impact factor: 3.448

Review 6.  Patient and clinician characteristics and preferences for increasing participation in placebo surgery trials: a scoping review of attributes to inform a discrete choice experiment.

Authors:  Madeleine Hinwood; Laura Wall; Danielle Lang; Zsolt J Balogh; Angela Smith; Michelle Dowsey; Phillip Clarke; Peter Choong; Samantha Bunzli; Francesco Paolucci
Journal:  Trials       Date:  2022-04-12       Impact factor: 2.279

7.  Ethical Issues in Intraoperative Neuroscience Research: Assessing Subjects' Recall of Informed Consent and Motivations for Participation.

Authors:  Anna Wexler; Rebekah J Choi; Ashwin G Ramayya; Nikhil Sharma; Brendan J McShane; Love Y Buch; Melanie P Donley-Fletcher; Joshua I Gold; Gordon H Baltuch; Sara Goering; Eran Klein
Journal:  AJOB Empir Bioeth       Date:  2021-07-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.